PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
暂无分享,去创建一个
K. Pasi | R. Klamroth | T. Lissitchkov | S. Knaub | J. Bichler | J. Windyga | A. Tiede | O. Walter | L. Nemes | L. Belyanskaya | L. Rusen | P. Georgiev | L. Gercheva | R. Klamroth | Pencho Georgiev | Jerzy Windyga | László Nemes | Andreas Tiede | Johann Bichler | Larisa Belyanskaya | Olaf Walter | Jerzy Windyga
[1] D. Andersson,et al. Efficacy and safety , 2018 .
[2] E. Santagostino,et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. , 2016, Blood.
[3] J. Oldenburg,et al. Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] Y. T. van der Schouw,et al. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates , 2016, Thrombosis and Haemostasis.
[5] R. Ljung,et al. Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels , 2016, Thrombosis and Haemostasis.
[6] J. Oldenburg,et al. Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] R. Liesner,et al. Novel, human cell line‐derived recombinant factor VIII (Human‐cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] S. Garger,et al. Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] B. Konkle,et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.
[10] L. Valentino. Considerations in individualizing prophylaxis in patients with haemophilia A , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[11] E. Berntorp,et al. Methods for individualising factor VIII dosing in prophylaxis , 2014, European journal of haematology. Supplementum.
[12] J. Dumont,et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.
[13] S. Pérez-Alenda,et al. Secondary prophylaxis vs. on‐demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre , 2014, Vox sanguinis.
[14] L. Valentino,et al. The first recombinant FVIII produced in human cells – an update on its clinical development programme , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[15] A. Klukowska,et al. Efficacy, Immunogenicity, Pharmacokinetics, and Safety Of Human-cl rhFVIII – a GCP Study In Children With Severe Haemophilia A , 2013 .
[16] C. Kempton,et al. Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) , 2013, Journal of thrombosis and haemostasis : JTH.
[17] M. Franchini. The modern treatment of haemophilia: a narrative review. , 2013, Blood transfusion = Trasfusione del sangue.
[18] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[19] M. Ramström,et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. , 2013, Thrombosis Research.
[20] O. Walter,et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. , 2012, Thrombosis research.
[21] K. Martinelle,et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics , 2012, European journal of haematology.
[22] J. Dumont,et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.
[23] L. Valentino,et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.
[24] M. Makris. Prophylaxis in haemophilia should be life-long. , 2012, Blood transfusion = Trasfusione del sangue.
[25] T. Humphries,et al. Consequences of Switching From Prophylactic Treatment to On-Demand Treatment in Late Teens and Early Adults with Severe Hemophilia A. the TEEN/TWEN Study , 2011 .
[26] M. Morfini,et al. Bioequivalence between two serum‐free recombinant factor VIII preparations (N8 and ADVATE®) – an open‐label, sequential dosing pharmacokinetic study in patients with severe haemophilia A , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[27] L. Mantovani,et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.
[28] M. Morfini,et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[29] A. Coppola,et al. Treatment of hemophilia: a review of current advances and ongoing issues , 2010, Journal of blood medicine.
[30] M. Morfini,et al. Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study , 2010, Journal of thrombosis and haemostasis : JTH.
[31] J. Stockman. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .
[32] M. van den Berg,et al. The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.
[33] P. Mannucci,et al. Modern treatment of haemophilia. , 1995, Bulletin of the World Health Organization.
[34] C H Chen,et al. A New Look at the Statistical Pattern Recognition. , 1977 .
[35] H. Akaike. A new look at the statistical model identification , 1974 .